Drug combo safety check in healthy volunteers
NCT ID NCT07425899
First seen Jun 27, 2026 · Last updated Aug 05, 2026 · Updated 2 times
Summary
This Phase 1 study tests how two oral drugs, ABBV-722 and upadacitinib, affect each other in the body. Thirty-two healthy adults will take multiple doses to measure drug levels and check for side effects. The goal is to understand safety and drug interactions, not to treat any disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- ABBV-722 and upadacitinib (oral drugs)
- What could go wrong
- This is an early-stage study in healthy people, not patients. It only checks drug levels and short-term safety, so it won't show if the drugs work for any disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEER are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Acpru /Id# 279285
Grayslake, Illinois, 60030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can eye movements reveal the Brain's visual priorities?
- A new eye on the brain: could this tracer unlock Addiction's secrets?
- First look: can a new drug candidate pass early safety tests in humans?
- A painless, contact-free vibration sensor may detect hidden heart and lung problems
- Can a Two-Pathway pill improve ED treatment? a new trial puts the combo to the test
- Could a common drug shield the brain from Alzheimer's?